Oligonucleotides

Polymers made up of a few (2-20) nucleotides. In molecular genetics, they refer to a short sequence synthesized to match a region where a mutation is known to occur, and then used as a probe (OLIGONUCLEOTIDE PROBES). (Dorland, 28th ed)

Also Known As:

Networked: 5145 relevant articles (178 outcomes, 534 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Agrawal, Sudhir: 21 articles (06/2017 - 01/2002)
2.	Wood, Matthew J A: 15 articles (10/2022 - 11/2008)
3.	Klinman, Dennis M: 15 articles (01/2021 - 05/2004)
4.	Wang, Hui: 15 articles (06/2007 - 01/2002)
5.	Aburatani, Hiroyuki: 14 articles (12/2007 - 01/2002)
6.	Zhang, Ruiwen: 14 articles (06/2007 - 01/2002)
7.	Mazurek, Urszula: 13 articles (11/2021 - 01/2006)
8.	Giordano, Thomas J: 13 articles (04/2010 - 08/2002)
9.	Hartmann, Gunther: 12 articles (03/2022 - 11/2002)
10.	Kuick, Rork: 12 articles (01/2009 - 08/2002)

Related Diseases

1.	Neoplasms (Cancer) 09/01/2012 - "To validate the tumor-promoting effect of miR-221, we showed that in vivo delivery of anti-miR-221 oligonucleotides leads to a significant reduction of the number and size of tumor nodules. " 04/15/2012 - "Vaccination of female mice with low doses of E7SOx combined with a CpG-rich oligonucleotide (ODN) as adjuvant elicits a strong long-lasting protection against E7-expressing tumor cells, preventing tumor outgrowth after rechallenge 90-days later. " 05/01/2001 - "The next logical steps include testing oligonucleotide efficacy against other tumor types, toxicological testing in higher species, and clinical trials in human subjects." 01/01/2023 - "qPCR data and cancer cell migration assays demonstrated higher knockdown efficacy when anti-miR-181a oligonucleotides were encapsulated and delivered using the VLPs resulting in reduced cancer cell invasiveness. " 01/01/2008 - "Here we review the key properties of LNA oligonucleotides in the context of their use as safe and effective antisense drugs and provide a status on their therapeutic development in the field of cancer."
2.	Infections 01/01/2008 - "The best results were obtained when the ODN were given within a few days around the infection, in contrast to former trials showing a time window of several weeks for significant oligonucleotide effects in non-infectious models. " 01/01/1993 - "This oligonucleotide caused a significant reduction (about 83%) of viroid infection even if the hybridization was done at a low (30 degrees C) temperature. " 09/01/2017 - "In this study, we investigated the immunostimulatory and protective effects of CpG motif oligonucleotides (CpG-ODNs) against Edwardsiella tarda infection in olive flounder (Paralichthys olivaceus). " 03/15/2002 - "However, if APCs were activated concomitantly in vivo using either anti-CD40 Abs or CpG oligonucleotides, the CTL responses induced were fully protective against infection with lymphocytic choriomeningitis virus or recombinant vaccinia virus. " 05/25/2022 - "Our prior studies in young mice showed optimal recruitment of CD8+ bTRM during neuroinvasive Listeria monocytogenes (Lm) infection required miR-155, and was significantly inhibited by anti-miR-155 oligonucleotides. "
3.	Prostatic Neoplasms (Prostate Cancer) 02/20/2013 - "Previously we reported that single-stranded oligonucleotides containing consensus STAT3 binding sequences (13410 and 13411) were more effective for inducing apoptosis in prostate cancer cells than antisense STAT3 oligonucleotides. " 06/01/2008 - "Previously, we reported that single-stranded oligonucleotides containing consensus STAT3 binding sequences (13410 and 13411) were more effective for inducing apoptosis in prostate cancer cells than antisense STAT3 oligonucleotides. " 11/01/2006 - "The present study was designed to demonstrate the therapeutic efficacy of a novel immunomodulatory oligonucleotide (IMO) for prostate cancer. " 08/01/2004 - "In this study, we tested whether interruption of MDM2 function using antisense MDM2 oligonucleotide (AS) affects the apoptotic response of prostate cancer cells to AD. " 01/01/2004 - "In this study, we used a triplex-forming oligonucleotide (TFO) to selectively inhibit Ets2 transcription in prostate cancer cells. "
4.	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 03/01/2018 - "Oligonucleotide-mediated splicing modulation is a promising therapeutic approach for Duchenne muscular dystrophy (DMD). " 06/16/2016 - "Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy." 01/01/2015 - "In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy." 10/01/2008 - "[Evaluation of multiplex PCR assay using dual priming oligonucleotide system for detection mutation in the Duchenne muscular dystrophy gene]." 08/01/2008 - "Exon-skipping oligonucleotides (ESOs) with 2'-O-methyl modifications are promising compounds for the treatment of Duchenne muscular dystrophy (DMD). "
5.	Glioma (Gliomas) 01/01/2012 - "Here we will discuss recent results on the use of oligonucleotides that will hopefully provide new effective treatment for gliomas." 11/14/2019 - "This study opens new frontiers for the in vitro evaluation and engineering of nanomedicines for delivery to the brain, and reports a systemically administered biodegradable nanocarrier for oligonucleotide delivery to treat glioma." 07/31/2003 - "In this study, we used Affymetrix high-density oligonucleotide arrays to identify the global gene expression signatures associated with gliomas of different types and grades. " 10/01/2002 - "This study was designed to evaluate the effects of antisense alpha 1, 4Gal-T oligonucleotide on human gliomas cell line SWO-38. " 01/01/2015 - "Oligonucleotide aptamers for glioma targeting: an update."

Related Drugs and Biologics

1.	RNA (Ribonucleic Acid)
2.	DNA (Deoxyribonucleic Acid)
3.	MicroRNAs (MicroRNA)
4.	Oligonucleotides
5.	Antisense Oligonucleotides
6.	Vaccines
7.	Messenger RNA (mRNA)
8.	Cytokines
9.	Peptides (Polypeptides)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Aftercare (After-Treatment)
5.	Injections